Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics

BACKGROUND: A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an oral prodrug of 5‐fluorouracil (5‐FU). Capecitabine and its metabolites are highly water‐soluble and, therefore, more likely to distribute to...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Molenaar‐Kuijsten, Laura, Jacobs, Bart Albertus Wilhelmus, Kurk, Sophie Alberdine, May, Anne Maria, Dorlo, Thomas Petrus Catharina, Beijnen, Jacob Hendrik, Steeghs, Neeltje, Huitema, Alwin Dagmar Redmar
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290233/
https://ncbi.nlm.nih.gov/pubmed/34121365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.4038
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak